Government-Owned Inventions; Availability for Licensing

Federal Register, Volume 85 Issue 2 (Friday, January 3, 2020)
[Federal Register Volume 85, Number 2 (Friday, January 3, 2020)]
[Pages 327-328]
From the Federal Register Online via the Government Publishing Office []
[FR Doc No: 2019-28358]
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with Vidita Choudhry, Ph.D., National Heart, Lung, and
Blood, Office of Technology Transfer and Development, 31 Center Drive,
Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-594-4095;
email: [email protected]. A signed Confidential Disclosure
Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Therapeutic and Diagnostic Targets for Severe RSV Infection
 Respiratory Syncytial Virus (RSV) infects nearly all children by
their second birthday. RSV usually causes mild respiratory illness,
however, a subset of patients experience severe infection that require
hospitalization. Successful host defense against viral pathogens
requires rapid recognition of the virus and activation of both innate
and adaptive immunity. Toll-Like Receptors (TLRs) are responsible for
mounting an innate immune response and genetic variations within TLRs
modulate severity of infection. Researchers at NIEHS have identified a
single nucleotide polymorphism (SNP) in TLR8 that is associated with
RSV disease severity. The SNP is p53-responsive allele, indicating that
p53, a master cell cycle regulator, can strongly influence TLR8
mediated immune responses. Identification of this SNP can inform
diagnosis and prognosis of RSV disease and serve as a therapeutic
target for severe RSV infection.
 Potential Commercial Applications:
[[Page 328]]
 Development of therapeutics against severe RSV infection
 Diagnostic biomarker
 Competitive Advantages:
 Enhance the innate immune response to respiratory infection
 Improve clinical trial outcome in patients with TLR8 mediated
RSV infection
 Development Stage:
 Early stage
 In vitro data available
 Inventors: Michael Resnick (NIEHS), Daniel Menendez (NIEHS), Steven
Kleeberger (NIEHS), and Fernando Polack (Infant Foundation).
 Intellectual Property: HHS Reference No. E-072-2019-0; US
Application No. 62/881,656.
 Licensing Contact: Vidita Choudhry, Ph.D.; 301-594-4095;
[email protected]. This notice is made in accordance with 35
U.S.C. 209 and 37 CFR part 404.
 Dated: December 26, 2019.
Vidita Choudhry,
Technology Development Specialist, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2019-28358 Filed 1-2-20; 8:45 am]